A securities fraud class action has been filed against PROCEPT BioRobotics (NASDAQ: PRCT), alleging undisclosed discount programs inflated handpiece sales and caused an 18% stock decline. Investors who purchased PRCT common stock between February 28, 2024 and February 25, 2026 have until September 22, 2026 to seek lead plaintiff status.
A securities fraud class action has been filed against PROCEPT BioRobotics (NASDAQ: PRCT), alleging undisclosed discount programs inflated handpiece sales and caused an 18% stock decline.
"Defendants misrepresented and/or failed to disclose that PROCEPT used a discount program to incentivize customers to place bulk orders in excess of demand," the complaint filed in the U.S. District Court for the Northern District of California alleges.
The lawsuit, captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691, covers investors who purchased PRCT common stock between February 28, 2024 and February 25, 2026. The complaint alleges handpiece sales exceeded procedures in every quarter since Q1 2023, creating cumulative excess field inventory of more than 10,000 units. On February 25, 2026, PROCEPT revealed U.S. handpiece unit sales contracted approximately 30% sequentially from 13,225 to 9,400 units.
The stock fell more than 18% over two days following the disclosure, from $27.84 to $22.69 per share. Investors have until September 22, 2026 to seek lead plaintiff status.
PROCEPT, a commercial-stage medical technology company focused on treating benign prostatic hyperplasia, sells its Aquablation therapy system with single-use handpieces disposed after each procedure. Handpiece unit sales serve as a key revenue driver and a proxy for procedure volume, making the discrepancy between sales and procedures material to investors. The company had previously stated that handpiece sales tracked procedure volumes and that customers "tend to order as they need product." The complaint alleges this characterization was false, as the discount program pulled forward demand at the expense of future periods.
The alleged channel stuffing surfaced progressively. On August 6, 2025, PROCEPT reported Q2 handpiece sales of approximately 12,750 units, missing consensus, and the stock fell 16% over two days from $45.69 to $38.41. On November 4, 2025, the company cut annual handpiece guidance by 1,000 units to 52,000 and admitted some customers were "probably carrying too much" inventory, sending shares down 10% from $35.02 to $31.30.
Multiple plaintiff firms — including Kessler Topaz Meltzer & Check, Bleichmar Fonti & Auld, Robbins Geller Rudman & Dowd, and Hagens Berman Sobol Shapiro — are soliciting investors to serve as lead plaintiff. The lead plaintiff is typically the investor or group with the largest financial interest in the case. The complaint also alleges that PROCEPT's stated 2025 handpiece sales and revenue guidance lacked a reasonable factual basis.
The lawsuit raises the risk of financial restatement and potential SEC scrutiny for PROCEPT. Investors will watch whether the company revises historical revenue figures or faces additional regulatory inquiries as the litigation advances toward the September 22 lead plaintiff deadline. The outcome could also affect how medical device companies disclose channel inventory practices.
This article is for informational purposes only and does not constitute investment advice.
